Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1993;88:1682-1690

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Counihan, P. J.
Right arrow Articles by McKenna, W. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Counihan, P. J.
Right arrow Articles by McKenna, W. J.

Circulation, Vol 88, 1682-1690, Copyright © 1993 by American Heart Association


ARTICLES

Assessment of heart rate variability in hypertrophic cardiomyopathy. Association with clinical and prognostic features

PJ Counihan, L Fei, Y Bashir, TG Farrell, GA Haywood and WJ McKenna
Department of Cardiological Sciences, St. George's Hospital Medical School, London, UK.

BACKGROUND. Altered vascular responses during exercise and disturbed responses to autonomic function testing have been documented in hypertrophic cardiomyopathy (HCM) and are associated with markers of an adverse prognosis. Reduced heart rate variability (HRV) and baroreflex sensitivity are predictors of increased risk of sudden death after myocardial infarction, but the value of these parameters in HCM is unknown. METHODS AND RESULTS. To determine the clinical significance of HRV and its relation to markers of electrical and hemodynamic instability in HCM, the 24-hour Holter recordings of 104 patients in sinus rhythm and off medication were analyzed. Five nonspectral measures of HRV were computed. The frequency components of HRV were calculated by fast Fourier transformation of the RR time intervals; the areas under the low (0.04 to 0.15 Hz) and high (0.15 to 0.4 Hz) frequency portions of the spectrum were measured as indices of autonomic and specific vagal influences on HRV, respectively. Spectral and nonspectral measures were compared with clinical, echo/Doppler, and Holter variables. ANCOVA was performed to allow for the effect of age on differences between variables. Spectral and nonspectral measures of HRV were correlated (r > .65; P < or = .001), indicating that the different time-domain and frequency parameters reflected similar measures of HRV. Global measures of HRV including the standard deviation of the mean of RR intervals (SDRR) and the standard deviation of 5-minute mean RR intervals (SDANN) were increased in patients with an adverse family history of HCM (173 +/- 67 vs 131 +/- 38 milliseconds, P = .001, and 158 +/- 66 vs 116 +/- 36 milliseconds, P = .004, respectively). In patients with exertional chest pain, global nonspectral measures were reduced compared with asymptomatic patients (118 +/- 31 vs 152 +/- 53 milliseconds, P = .006, and 105 +/- 30 vs 136 +/- 52 milliseconds, P = .014, respectively). Specific vagal influences on HRV including the proportion of RR intervals more than 50 milliseconds different (PNN50) and the high frequency peak on spectral analysis were less in patients with supraventricular arrhythmias on Holter monitoring (7.2 +/- 8 vs 16 +/- 13%, P = .012, and 21 +/- 10 vs 28 +/- 13 milliseconds, P = .048, respectively). Similarly, both global and specific vagal measures of HRV were less in the 27 patients with nonsustained ventricular tachycardia on Holter (PNN50, 7.7 +/- 9 vs 15 +/- 13 milliseconds, P = .048, and high frequency component, 19 +/- 9 vs 28 +/- 13 milliseconds, P = .05. During follow-up, 10 patients, 9 of whom were aged less than 33 years, experienced catastrophic events; 6 were resuscitated from ventricular fibrillation and 4 died suddenly. Indices of HRV were similar in these 10 patients to indices in the 94 survivors. CONCLUSIONS. Time-domain and spectral measures of HRV yield similar information about the specific autonomic influences on the heart. Global and specific vagal influences on HRV were reduced in patients with symptoms and arrhythmias and global HRV is increased in patients with an adverse family history of HCM, but these indices do not add to the predictive accuracy of established risk factors.


This article has been cited by other articles:


Home page
QJMHome page
M.J. Reed, C.E. Robertson, and P.S. Addison
Heart rate variability measurements and the prediction of ventricular arrhythmias
QJM, February 1, 2005; 98(2): 87 - 95.
[Full Text] [PDF]


Home page
Cardiovasc ResHome page
R.C. Saumarez and A.A. Grace
Paced ventricular electrogram fractionation and sudden death in hypertrophic cardiomyopathy and other non-coronary heart diseases
Cardiovasc Res, July 1, 2000; 47(1): 11 - 22.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. H. Crawford, S. J. Bernstein, P. C. Deedwania, J. P. DiMarco, K. J. Ferrick, A. Garson Jr, L. A. Green, H. L. Greene, M. J. Silka, P. H. Stone, et al.
ACC/AHA guidelines for ambulatory electrocardiography: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the Guidelines for Ambulatory Electrocardiography) developed in collaboration with the North American Society for Pacing and Electrophysiology
J. Am. Coll. Cardiol., September 1, 1999; 34(3): 912 - 948.
[Full Text] [PDF]


Home page
HeartHome page
F LOMBARDI and A MORTARA
Heart rate variability and cardiac failure
Heart, September 1, 1998; 80(3): 213 - 214.
[Full Text]


Home page
HeartHome page
K PRASAD and M P FRENNEAUX
Sudden death in hypertrophic cardiomyopathy: potential importance of altered autonomic control of vasculature
Heart, June 1, 1998; 79(6): 538 - 540.
[Full Text]


Home page
CirculationHome page
T. F. o. t. E. S. o. C. t. N. A. S. o. P. Electrophysiology
Heart Rate Variability : Standards of Measurement, Physiological Interpretation, and Clinical Use
Circulation, March 1, 1996; 93(5): 1043 - 1065.
[Full Text]